問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
張經緯
下載
2023-01-05 - 2026-12-13
Condition/Disease
Test Drug
Participate Sites5Sites
Recruiting5Sites
2020-08-17 - 2023-12-12
Participate Sites6Sites
Recruiting6Sites
2022-05-02 - 2023-04-18
2019-03-01 - 2024-12-26
Participate Sites9Sites
Recruiting9Sites
2020-06-30 - 2024-10-11
To verify the efficacy of Toripalimab combined with Bevacizumab as the firstline therapy for advanced hepatocellular carcinoma (HCC).
Toripalimab (JS001)
Participate Sites3Sites
Recruiting3Sites
全部